Core Viewpoint - The Ministry of Industry and Information Technology (MIIT) has issued the "Computing Power Interconnection Action Plan" to promote the application of computing power interconnection in various new business scenarios [1] Group 1: Application Scenarios - The plan emphasizes the application of computing power interconnection in service scenarios such as computing resource services, task scheduling, market transactions, and open-source community operations [1] - It aims to enhance enterprise-level applications in artificial intelligence, scientific computing, intelligent manufacturing, remote medical services, and visual internet [1] - The initiative also targets consumer-level applications including intelligent driving, cloud rendering, cloud computing, and cloud gaming [1] Group 2: Integration with Other Technologies - The plan encourages the integration and innovative application of computing power interconnection with energy internet, industrial internet, and mobile internet [1]

Core Insights - Andrew Dudum, co-founder of Hims & Hers, transitioned from a background in music to entrepreneurship, driven by a passion for business and innovation [1][3] - Hims & Hers has emerged as a leading telehealth provider, focusing on destigmatizing healthcare and providing convenient access to medical services [5][6] Group 1: Early Life and Education - Andrew Dudum was born in 1988 in San Francisco and was influenced by a family environment rich in entrepreneurial spirit [1] - He attended the Wharton School of the University of Pennsylvania, where he co-founded his first business, LendforPeace, aimed at supporting small businesses in the Middle East [1][3] Group 2: Founding Atomic Labs - In 2013, Dudum co-founded Atomic Labs, a unique company that combines startup incubation and venture capital, focusing on creating companies from internal concepts [4] - Atomic Labs has successfully launched over ten startups, with Hims being one of the most notable successes [4] Group 3: Development of Hims & Hers - Hims was founded in 2016 to address gaps in the healthcare market, particularly in the areas of hair loss and sexual health, initially targeting male consumers [5] - The brand has since expanded to include female healthcare services and aims to provide a broad range of telehealth solutions [5] Group 4: Financial Growth and Market Position - Hims & Hers went public in 2021 through a merger with a SPAC, achieving a valuation of $1.6 billion at the time of listing [5] - As of May 2023, Hims & Hers reported a revenue increase of 111%, reaching $586 million, with net income rising from $11.1 million to $49.5 million [7]

Summary of Concentra Group Holdings Parent (CON) 2025 Conference Call Company Overview - Concentra is the largest primary care provider of occupational health care services in the United States, focusing on workplace health and injury management [1][2] - The company treats approximately 20% of all workers' compensation injuries in the U.S., working with over 215,000 employers [3][4] Core Business Lines - **Workers' Compensation Services**: - Majority of visits are related to musculoskeletal injuries, with 40-50% referred to therapy [7][8] - Reimbursement is based on state fee schedules, which vary by state [10][11] - **Employer Services**: - Includes drug screenings and physicals, with direct negotiations for pricing with employers [12][9] - Services are fee-for-service, with no capitation or at-risk payments [13] - **On-site Services and Telemedicine**: - Concentra offers on-site health services at employer locations and a telemedicine platform, expanding their service offerings [16][17] Financial Performance and Growth Strategy - Revenue growth is targeted in the mid to high single digits, driven by same-center visits, pricing adjustments, and small acquisitions [18][21] - Workers' compensation volumes were flat in Q1, but positive growth was observed in subsequent months [22][23] - Employer Services experienced a decline post-COVID but showed signs of recovery with a 10-15% increase in volume [25][46] Market Dynamics - The company operates in a diversified market, with no single industry representing more than 10% of revenues [29] - Historical resilience during economic downturns, with modest declines in EBITDA during the global financial crisis [30][31] Pricing and Rate Adjustments - Workers' compensation rates are influenced by state fee schedules, with an average growth of 3% historically [19][37] - Approximately 20 states have a Consumer Price Index (CPI) or Medical Economic Index (MEI) tied to their fee schedules, allowing for potential rate increases in line with inflation [39][40] Future Outlook - Positive trends in both workers' compensation and employer services are expected to continue, contingent on economic stability [27][47] - The company is focused on integrating recent acquisitions and reducing leverage, targeting a leverage ratio of 3.0x within 18-24 months [62][63] Additional Insights - The company is exploring new service offerings, such as background checks, to enhance employer services [53] - Behavioral health services are being expanded through telemedicine, reflecting growing demand [59] This summary encapsulates the key points discussed during the conference call, highlighting Concentra's business model, financial performance, market dynamics, and future growth strategies.

Financial Data and Key Metrics Changes - LifeMD achieved total revenues of $65.7 million, a 49% increase year over year [12] - Core telehealth revenue grew by 70% compared to the prior year, with adjusted EBITDA of $5.3 million, a significant improvement from a loss of $1.3 million in the same period last year [12][15] - GAAP net income attributable to common stockholders was $608,000, compared to a net loss of $7.5 million in the first quarter of 2024 [14] - Adjusted EBITDA totaled $8.7 million for the first quarter, compared to $100,000 in the year-ago period [15] - Gross margin for the first quarter was 86.8%, a decline of 270 basis points year over year but an increase of 150 basis points sequentially [12][13] Business Line Data and Key Metrics Changes - The telehealth business saw a 22% increase in active subscribers, reaching over 290,000 [12] - WorkSimply active subscribers declined by 5% to 158,000, but the business continued to perform well financially with quarterly adjusted EBITDA exceeding $3 million [12] - The RExMD brand showed consistent growth in revenue and active patient count, reinforcing its position in men's health [5] Market Data and Key Metrics Changes - LifeMD expanded coverage to over 21 million Medicare Part B beneficiaries across 26 states, with plans to reach 49 states and over 60 million beneficiaries by the end of Q2 [9] - The company is entering high-growth verticals such as women's health and behavioral health, with new offerings expected to launch soon [10][11] Company Strategy and Development Direction - LifeMD aims to build a trusted vertically integrated marketplace for healthcare services, prescription medications, and over-the-counter health products [17] - The company is expanding its offerings beyond sexual health into weight management, behavioral health, insomnia, and hormone replacement therapy [6][10] - Strategic collaborations with Lilly Direct and NovoCare are intended to improve access to GLP-1 medications for weight management patients [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's trajectory for the remainder of the year, citing strong early traction across key initiatives [17] - The company is focused on delivering high-quality virtual care and enhancing patient experience through technology and a mission-driven team [18] - Management highlighted the importance of insurance in their offerings, believing it will drive retention and expand the total addressable market [28] Other Important Information - LifeMD's cash position at the end of the first quarter was $34.4 million [16] - The company raised its financial guidance for 2025 due to the outperformance of its telehealth business [16] Q&A Session Summary Question: Can you talk about your relationships with Lilly and Novo? - Management clarified that the pricing for medications is the same for patients regardless of the source, and there are no discounts or rebates from drug manufacturers [23][24] Question: Can you discuss the role of insurance in your offerings? - Management emphasized the importance of insurance in making care more accessible and driving retention, while also acknowledging the complexity of integrating cash pay and insurance offerings [28] Question: What were the main drivers of earnings upside compared to expectations? - The main driver was higher-than-expected retention revenue, with a small contribution from increased acquisitions in the weight management space [31][32] Question: Can you provide an update on your compounding pharmacy? - The compounding pharmacy is on track for licensing, with expectations to scale the mail order pharmacy significantly [33] Question: Does your 2025 guidance include contributions from mental health and women's health? - Yes, but the contributions are expected to be minimal initially, with growth anticipated as the offerings are fully integrated [38] Question: How much of the positive guidance revision is related to the recent pharmacy announcement? - The guidance revision is primarily based on Q1 performance, with potential long-term benefits from the partnerships not yet incorporated into guidance [44][45] Question: How will patients choose between Wegovy and Zepbound? - Patient choice will not affect LifeMD's revenue, as both therapies are offered based on clinical recommendations [50] Question: Will LifeMD continue to offer compounded GLP-1 in the coming years? - LifeMD does not compound GLP-1 medications but will assist patients in accessing branded therapies [56]

Group 1 - Hims & Hers Health Inc (NYSE:HIMS) reported a 300% increase in net profits for the first quarter, surpassing both top- and bottom-line estimates [1] - Despite a negative outlook, HIMS received four price-target increases, including a rise from Leerink Partners to $42 from $40 [1] - HIMS shares rose 9.9% to $46.06, recovering from premarket losses and reaching their highest level since February [1][3] Group 2 - Options trading activity is significantly high, with 267,000 calls and 188,000 puts traded, which is six times the average intraday volume [2] - The most popular options contracts are the weekly 5/9 45-strike call and the 50-strike call, with new positions being opened [2] - HIMS is on track for its fourth consecutive daily gain, consolidating above the 60-day moving average and showing a 296% year-over-year increase [3] Group 3 - Short interest in HIMS has increased by 10.8% in the last two reporting periods, with 60.88 million shares sold short, representing 31.9% of the equity's available float [7] - There is potential for a short squeeze if the current pessimism begins to unwind, which could lead to further price increases for HIMS [7]

Core Insights - American Well Corporation (AMWL) reported revenue of $66.83 million for the quarter ended March 2025, reflecting a year-over-year increase of 12.3% and exceeding the Zacks Consensus Estimate by 11.18% [1] - The company's EPS was -$1.73, an improvement from -$5.00 in the same quarter last year, with a surprise of 44.01% compared to the consensus estimate of -$3.09 [1] Revenue Breakdown - Platform subscription revenue was $32.21 million, slightly below the average estimate of $32.89 million, but showed a year-over-year increase of 29.6% [4] - Other revenue reached $8 million, significantly surpassing the average estimate of $3.61 million, marking a year-over-year increase of 122.8% [4] - Revenue from visits was $26.63 million, which was above the average estimate of $23.70 million, but represented a year-over-year decline of 14.3% [4] Stock Performance - Over the past month, shares of American Well have returned +2.5%, contrasting with a -0.7% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Insights - Teladoc reported revenue of $629.37 million for Q1 2025, a decrease of 2.6% year-over-year, with an EPS of -$0.19, an improvement from -$0.49 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $617.67 million by 1.89%, while the EPS surpassed the consensus estimate of -$0.33 by 42.42% [1] Financial Performance Metrics - Average Revenue Per U.S. Integrated Care Member was $1.27, matching the five-analyst average estimate [4] - U.S. Integrated Care Members reached 102.5 million, exceeding the five-analyst average estimate of 101.3 million [4] - BetterHelp Paying Users totaled 0.4 million, slightly above the estimated 0.39 million [4] - Chronic Care Program Enrollment was 1.15 million, below the average estimate of 1.19 million [4] Revenue by Segment - Teladoc Health Integrated Care generated $389.47 million, surpassing the $380.91 million average estimate, reflecting a year-over-year increase of 3.3% [4] - BetterHelp reported revenues of $239.90 million, slightly above the $237.29 million estimate, but down 10.8% year-over-year [4] - BetterHelp-Other Wellness Services generated $5.46 million, below the three-analyst average estimate of $5.87 million, with a year-over-year increase of 2.9% [4] - BetterHelp-Therapy Services reported $234.44 million, exceeding the $231.85 million estimate, but down 11.1% from the previous year [4] Revenue by Type - Revenue from Other sources was $103.63 million, significantly above the two-analyst average estimate of $84.31 million, marking a year-over-year increase of 16.5% [4] - Access fees generated $525.74 million, below the $533.56 million average estimate, representing a year-over-year decline of 5.6% [4] Adjusted EBITDA - Adjusted EBITDA for BetterHelp was $7.71 million, slightly below the $7.93 million average estimate [4] - Adjusted EBITDA for Teladoc Health Integrated Care was $50.38 million, exceeding the five-analyst average estimate of $46.02 million [4]

Financial Performance - LifeMD achieved a consolidated revenue growth of 43% year-over-year, reaching $64.3 million in Q4 2024, with telehealth revenue growing by 60% [30] - The company reported a standalone adjusted EBITDA profitability of $5.9 million for telehealth, an increase of 396% compared to the previous year [30] - For the full year 2024, consolidated revenue was $212.5 million, a 39% increase from 2023, with telehealth revenue growing by 61% [35] Business Line Performance - Telehealth revenue grew significantly, with active subscribers increasing by 27% year-over-year to over 275,000 [31] - WorkSimpli's active subscribers grew by 3% to 164,000, stabilizing with an average monthly adjusted EBITDA of over $1 million [31] - The male hormone replacement therapy business was successfully launched, contributing to the growth of the Rex MD platform, which currently produces over $80 million in annualized revenue [19][20] Market Data - LifeMD's weight loss and metabolic health program had over 75,000 active patients by year-end, positioning the company for long-term growth [9] - The approval rate for Zepbound, a GLP-1 medication, increased by 18 percentage points between October and January, reaching nearly 60% [12] - The company expects to have approximately 150 million lives under coverage by the end of 2025, expanding its addressable market significantly [24] Company Strategy and Industry Competition - LifeMD's strategic priorities for 2025 include solidifying its market position in weight loss and metabolic care, expanding hormone replacement therapy offerings, and launching the LifeMD plus membership program [8] - The company aims to enhance its pharmacy capabilities and expand its insurance offerings to drive more affordable access to virtual care [21][23] - LifeMD is well-positioned to benefit from the fragmentation in the GLP-1 supported weight loss market, as many smaller players may struggle to adapt [18] Management Commentary on Operating Environment and Future Outlook - Management expressed optimism about the future, highlighting the strong performance in telehealth and the addition of key capabilities like pharmacy and insurance offerings [39] - The company is preparing for potential Medicare coverage of GLP-1 medications, which could significantly impact its business [70] - Management emphasized the importance of providing affordable access to medications and comprehensive care for patients [123] Other Important Information - The gross margin for Q4 was 85.3%, a decline of 280 basis points due to changes in revenue mix and one-time impacts from onboarding a new pharmacy [32] - LifeMD expects gross margins to normalize to 88% to 90% in 2025 [32] - The company plans to launch several new service offerings in 2025, including behavioral health services and an enhanced virtual care membership program [25][28] Q&A Session Summary Question: Can you talk about your relationship with LillyDirect and how it works? - LifeMD has a relationship with a third-party pharmacy used by LillyDirect to ship medications directly to patients, enhancing patient experience for those without insurance coverage [44] Question: What is your outlook for the future of WorkSimpli? - WorkSimpli has stabilized and is expected to continue producing around $1 million in EBITDA monthly, with significant growth potential [66] Question: What percentage of new patients are getting insurance approvals for therapies? - Approximately 10% of patients receive coverage without prior authorization, while about 60% require prior authorization, with a favorable approval rate for Zepbound [117] Question: What are the assumptions in your 2025 revenue guidance? - The guidance includes conservative estimates for patient retention and assumes a significant portion of growth will come from new patients transitioning to branded therapies [87] Question: Can you provide an update on Medicare reimbursement for telehealth services? - There is optimism for a permanent extension of Medicare coverage for telehealth, with bipartisan support in the legislature [73] Question: What is the expected contribution from the new behavioral health program? - The behavioral health market is seen as a significant opportunity, with plans to offer comprehensive treatment options [76]

As filed with the Securities and Exchange Commission on November 6, 2023. Registration No. 333-274606 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 3 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KINDLY MD, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Utah 8049 84-3829824 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No.) 5097 ...

As filed with the Securities and Exchange Commission on [ ], 2023. Registration No. 333- (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KINDLY MD, INC. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (I.R.S. Employer Identification No.) 5097 South 900 East Suite 100 Salt Lake City, UT 84117 (38 ...